9th Annual CAR-TCR Summit
The is a premier event designed for the cell therapy industry to address key challenges such as manufacturing efficiency, safety, and cost-effectiveness. It offers in-depth insights and networking opportunities for professionals across various stages of cell therapy development, with a focus on discussing and overcoming industry challenges alongside leading experts and academics.
Date: September 17-20, 2024
Location: Hynes Convention Center, Boston, MA
Booth: #60
JOIN US!
Visit ×îÐÂÉ«ÇéӰƬ’s Booth (#60) to explore our UpTempoâ„ platform process, designed to enhance the efficiency and scalability of your cell therapy manufacturing processes.
Engage with our experts to learn how ×îÐÂÉ«ÇéӰƬ’s innovative solutions can improve safety, reduce costs, and accelerate product release times for your cell therapy pipelines. Complete the form to schedule a meeting with ×îÐÂÉ«ÇéӰƬ Cell Therapy experts at the 9th Annual CAR-TCR Summit!
FEATURED SPEAKING SESSION
Title: Decentralized Manufacturing Leveraging Platform Innovation and Commercialization for CAR-T and TCR-T Therapy
Date: September 19, 2024
Time: 11:05-11:15 am EDT
Key Learning Points:
- Autologous Cell Therapy Product: UpTempoâ„ Autologous CAR-T Platform – Advanced GMP compliant CAR-T workflow
- Allogeneic Cell Therapy Product: iPSC Platform – 1] GMP compliant iPSC lines 2] iPSC derived cell therapy differentiation protocols
- CAR-T and TCR-T Therapy Analytical QC Package
SPEAKER
Junxia Wang, Ph.D.
Senior Director
Product Development
×îÐÂÉ«ÇéӰƬ Cell Therapy
ABOUT CATALENT CELL & GENE THERAPY
×îÐÂÉ«ÇéӰƬ Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vaccines, ×îÐÂÉ«ÇéӰƬ is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. As an experienced and innovative partner, it has a global network of dedicated, development, clinical, and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, and fill/finish capabilities located in the U.S. and Europe. With integrated solutions for plasmid DNA, viral vectors, and autologous and allogeneic cell therapies through clinical trial packaging and logistics, ×îÐÂÉ«ÇéӰƬ can provide full supply chain control, helping innovators get their advanced therapies to patients, faster.
